Skip to main content
. 2014 Jul 25;5(16):6801–6815. doi: 10.18632/oncotarget.2254

Figure 2. AZD1480 inhibits the growth of subcutaneously implanted MO4 melanoma tumors and prolongs survival of tumor-bearing mice by inhibiting P-STAT3 expression within the tumor environment.

Figure 2

MO4 tumor-bearing mice were treated with AZD1480 at 30 mg/kg or vehicle control by oral gavage bid for 7 days. A. Individual growth curves of melanoma tumor-bearing mice treated with vehicle control (left panel) or AZD1480 (middle panel). Mean tumor volume of mice treated with vehicle control or AZD1480 is shown in the right panel. One representative of 2 independent experiments with each time 5 mice per group is shown. B. Survival curve of MO4 tumor-bearing mice treated with vehicle control or AZD1480. One representative of 2 independent experiments with each time 5 mice per group is shown. C. Two mice of each treatment group were sacrificed 2 hours after the last dosing and whole-cell lysates were prepared and subjected to western blot analysis for the expression of P-STAT3. One representative blot of 2 independent experiments is shown.